Clinical Trial Update: Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating alemtuzumab in combination chemotherapy for untreated acute lymphoblastic leukemia; completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Alemtuzumab (Alemtuzumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Undifferentiated Leukemia, B-cell Adult Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-04-16